Jennifer Giltnane, MD, PhD

Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI. https://lnkd.in/eDzU4m8e?

1

Have you seen the latest issue of the Journal of the National Comprehensive Cancer Network® (NCCN®)? There is a must-read article on research conducted by some of our brilliant team at Evidera!

14

When it comes to clinical trials, we know every day saved in development and enrollment timelines is a day closer to bringing new treatments to patients. Labcorp’s diagnostic data empowers your team to make informed decisions that can enhance trial design and recruitment. From identifying the best high-volume sites for your study to accelerating the rate of enrollment, our data provides the answers to drive your health innovation forward. Learn more about Labcorp’s clinical trial enablement services. #ClinicalTrials #ClinicalResearch #ClinicalStudies #ClinicalTrialsDay

40

Call for Papers 🔬 🧬 In collaboration with an outstanding team of Associate Editors at Frontiers in Immunology (current IF 7.3) and Frontiers in Oncology (current IF 4.7), we are hosting a Research Topic within the Cancer Immunity and Immunotherapy journal sections entitled “Clinical Implementation of Precision Oncology Data to Direct Individualized and Immunotherapy-Based Treatment Strategies”. If you have research to submit for publication now or in the coming months, please consider submission through our Research Topic. I am including the link below for a full description of scope, but we are generally looking to publish a multidisciplinary article collection covering research advancements and review articles in precision oncology that have an immunotherapy-associated focus. If you have questions, please don't hesitate to reach out to me directly. Despite recent advancements, clinical implementation of scientific discoveries from novel, commercially developed laboratory tests has been suboptimal and inefficient. Since FDA approvals of cancer therapeutics will be more commonly tumor-agnostic moving forward, physicians will require a better understanding of commercially available clinical tests to be confident in using the results to guide treatment decisions. Through the publication of this journal collection, the medical community will have a better understanding of the precision oncology testing landscape and the clinical data indicating efficacy with treatment, which could facilitate more widespread future utilization in conventional clinical care. https://lnkd.in/g-uvWqi5

8

A new study in Med by Cell Press looked at how often mutations occur in different genes linked to cancer, and compared this to how much research funding and how many publications focused on those genes. The authors found basically no connection. This suggests that cancer research might not be focusing on the most common mutations, and that researchers and funders might want to consider changing how they allocate resources. #cancerresearch #fundingpriorities https://lnkd.in/eBN9VdZ6

8

FDA adverse event study shows JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://buff.ly/3xS9dV9

1

Protocol-based disease registries are purpose-built for research, making them one of the most clinically rich sources of RWD - learn how to leverage them in this on demand webinar.

2

Our joint G2 Intelligence / Today's Clinical Lab webinar on the FDA's final LDTs rule is just over 24 hours away! I recently chatted via email with one of our speakers, regulatory expert Shannon Bennett, to get his initial thoughts on the final rule. Here's what he had to say about what was most surprising about the rule, what labs may find most challenging, and what labs should do right away to prepare: https://lnkd.in/gw3WuQjM #LDTs #FDA #ClinicalLaboratory #MedicalLaboratory

10

Exciting times ahead in gene therapy! 🧬✨ Regeneron has just announced a colossal partnership with Mammoth Biosciences, spotlighting a promising future for CRISPR-based in vivo gene editing treatments. This dynamic duo is bringing together Regeneron's state-of-the-art viral vectors and Mammoth's cutting-edge compact nucleases to forge treatments with precision targeting. The deal includes a whopping $100 million upfront with an additional $370 million for milestones, plus royalties. That's a serious investment in next-gen healthcare. Dr. Christos Kyratsous from Regeneron cites years of groundwork laying the foundation for this collaboration, set to align the delivery systems with specific diseases for optimal outcomes. With equity involved and the option for Mammoth to co-fund and profit-share, the deal embodies a true symbiotic spirit. As the second major gene editing stride for Regeneron, after its ongoing work with Intellia Therapeutics, we're witnessing an exhilarating era where the potential for breakthrough therapies is skyrocketing. This is game-changing science with patient lives ready to be profoundly impacted! #GeneTherapy #CRISPR #Innovation #Healthcare

27

1 Comment

I cannot emphasize enough the importance of first formulating research questions and then identifying the fit-for-purpose RWD for analysis—in this order. Defining the right questions, understanding RWD databases and their limitations, and deciding on the RWE study design are key to successfully applying RWD/RWE. The table below is from the ASCPT Workshop on RWD and RWE. Definitely worth a read. 👉 Link here: https://lnkd.in/eXMNgQZM

31

I'm presenting our research at the American Society of Clinical Oncology (ASCO) annual meeting today on a machine learning algorithm that can predict microsatellite instability status using genomic and gene expression data using the Labcorp OmniSeq INSIGHT assay: https://lnkd.in/eybvFPFY Immunotherapies can have a marked and robust effect in the treatment of certain cancers, particularly those that harbor defects in DNA mismatch repair and cause mutations in microsatellite sites. There are many ways to test for this abnormality, and a major test is performed using direct Next Generation Sequencing of the sites, but sometimes this component fails due to the repetitive nature of these short DNA sequences. My colleagues and I have developed a machine learning algorithm that can use data gathered from other test components and predict whether a tumor is Microsatellite-Unstable with a high degree of accuracy across different tumor types. It's a small yet interesting and potentially useful application of AI to cancer therapy. I will be at poster #425 on Saturday morning -- please stop by if you're interested or just want to say hello. I look forward to meeting you! #ASCO2024, Eric Severson, Shakti Ramkissoon, Zachary Wallen, PhD, Sarabjot Pabla, Rebecca Previs, Heidi Ko, DO, Jeffrey Conroy, Mary K Nesline, Pratheesh Sathyan PhD, Kamal S. Saini, Taylor Jensen, Margot Schoenborn, Marcia Eisenberg, Brian Caveney

99

A liver digital twin that can be used for in silico prediction of cellular and intercellular interactions during regeneration following DILI Digital twins are built to predict and describe molecular, cellular, and tissular responses in pathophysiology Could digital twins help identify new areas of research and potential therapeutics? https://lnkd.in/gz2i7M6Y

8

A guide to meeting the sharing requirements of the NIH Data Management and Sharing plan. View data repositories as collaborators in achieving your goals rather than passive storage spaces https://lnkd.in/gKJVF_X6

11

1 Comment

Remember to register for this upcoming #webinar from The Evidence Base® - The Goldilocks problem in oncology RWD: choosing the data that’s ‘just right’ Register: https://lnkd.in/eecGa6YD Join Wendy Turenne (Aetion), Mark Shapiro (xCures) and Andrew Belli (COTA) discuss the intricacies of #oncology care and the measurable #outcomes captured through #RWD. Dive deep into the most critical elements for oncology, such as #biomarkers, progression and mortality, and learn about strategies for extracting insights from unstructured #EMR data, such as clinical #genomic data and #medicalimages. #heor #healtheconomics #outcomesresearch #rwe #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy #electronicmedicalrecords

24

2 Comments

𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐀𝐫𝐫𝐡𝐲𝐭𝐡𝐦𝐢𝐚𝐬: 𝐏𝐮𝐥𝐬𝐞𝐝-𝐅𝐢𝐞𝐥𝐝-𝐀𝐛𝐥𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 🫀 The market for the use of #PFA (#PulsedFieldAblation) Technologies for the treatment of #CardiacArrhythmias is hotting up! With #HRS2024 kicking off in Boston, this is an area that has garnered a lot of attention in #cardiology, and #electrophysiology circles in particular, for the effective treatment of #Afib (#AtrialFibrillation). 𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐬𝐭𝐚𝐭𝐬 𝐲𝐨𝐮 𝐬𝐡𝐨𝐮𝐥𝐝 𝐤𝐧𝐨𝐰 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐭𝐞𝐜𝐡: • Clinical evidence supports excellent efficacy, with #pulmonaryvein isolation achieved in almost all patients. • Low rate of major complications (including #pericardialtamponade, #stroke and #coronary spasm) • Significantly faster procedure time than #cryoablation or #radiofrequency (#RF) ablation • Good overall freedom from #AFib after one year for #paroxysmal and persistent #AF 𝐑𝐞𝐜𝐞𝐧𝐭 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐬𝐩𝐚𝐜𝐞 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Boston Scientific sparks 70% #electrophysiology growth after #Farapulse pulsed-field #ablation launch 🫀 https://shorturl.at/loAVZ Johnson & Johnson secures European #afib #CE approval for #Varipulse pulsed field ablation system 🫀 https://shorturl.at/gtyGY Abbott joins the #pulsedfieldablation party with first procedures using the #Volt #PFA system 🫀 https://shorturl.at/eJNUZ Medtronic nets approval in Japan for #pulsedfieldablation system 🫀 https://shorturl.at/hktER ...𝐚𝐧𝐝 𝐡𝐞𝐫𝐞'𝐬 𝐚𝐧 𝐞𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐨𝐧𝐞: Field Medical Announces First-in-Human (#FIH) Trials for Groundbreaking #FieldForce™ #Ventricular Pulsed Field Ablation Technology. The first and only #PFA system designed for the treatment of #VentricularArrhythmias. 🫀 https://shorturl.at/swGP4 #medtech #medicaldevices #hrs #heartrhythmsociety #cardiology #electrophysiology #cardiacrhythmmanagement #cardiovascular #healthtech #heartfailure #healthcare #innovation #executivesearch #executiverecruitment #cardiacablation #cardiacarrhythmia

94

3 Comments

While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily

5

Interesting developments regarding multiple applications of mistletoe in oncology. https://lnkd.in/gv-CeJSH For the 40% of bladder cancer not responsive to BCG, intravesical, intravenous and subcutaneous instillation of mistletoe is a promising treatment that should be carefully evaluated along with intravenous ascorbate.

16

1 Comment